FDA requests market withdrawal of all ranitidine products

被引：0

作者：

机构：

来源：

Reactions Weekly | 2020年 / 1799卷 / 1期

关键词：

D O I：

10.1007/s40278-020-77006-4

中图分类号：

学科分类号：

摘要：

引用

页码：4 / 4

共 50 条

[31] FDA WITHDRAWAL OF PROPOXYPHENE FROM THE MARKET: CLINICAL REACTIONS AND POLICIES AT ONE ACADEMIC MEDICAL CENTER
Wofford, James L.
Kirk, Julienne
Feiereisel, Kirsten
Miller, David P.
JOURNAL OF GENERAL INTERNAL MEDICINE, 2011, 26 : S330 - S330
[32] Characteristics of breakthrough therapy designation requests (BTDRs) submitted to the Office of Hematology and Oncology Products (OHOP), FDA.
Suzman, Daniel L.
Kluetz, Paul Gustav
Mckee, Amy E.
Ward, Ashley Flynn
Marcus, Leigh Jessica
Casak, Sandra J.
Pazdur, Richard
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[33] Effects of the FDA's sodium reduction strategy in the US market for chip products
Staudigel, Matthias
Anders, Sven
JOURNAL OF ECONOMIC BEHAVIOR & ORGANIZATION, 2020, 173 : 216 - 238
[34] FDA requires boxed warning for all immediate-release opioid products
Thompson, Cheryl A.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (09) : E114 - E115
[35] Creative market solutions from customer requests: Simple ideas can lead to big products
Cheeseright, Tim
Scoffin, Robert
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
[36] FDA requests revisions in Biologics License Application for tositumomab
不详
BIOTECHNOLOGY LAW REPORT, 2000, 19 (01) : 34 - 35
[37] FDA requests class label change for atypical antipsychotics
Reactions Weekly, 2003, 970 (1) : 2 - 2
[38] FDA requests nominations for radiological devices, other panels
不详
JOURNAL OF NUCLEAR MEDICINE, 2005, 46 (10) : 26N - 27N
[39] FDA rejects industry requests for food label revisions
不详
JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, 1999, 99 (10) : 1206 - 1206
[40] FDA requests inclusion of new warnings for ADHD medications
Ralat, Jose
CNS SPECTRUMS, 2006, 11 (10) : 739 - 739

← 1 2 3 4 5 →